AXIM Biotechnologies has filed an Emergency Use Authorisation (EUA) application with the US Food and Drug Administration (FDA) for its first-in-class rapid diagnostic test for Covid-19. AXIM’s rapid diagnostic test is expected to be the market’s first Covid-19 rapid diagnostic test which measuring levels of functional neutralising antibodies in a lateral flow assay format.

Color has secured EUA from the FDA that allows CLIA-certified laboratories designated by the company use its self-swab Covid-19 collection kit. Patients will be able to collect their own samples at home, or onsite at workplaces or other congregate settings, without needing healthcare professionals to monitor the sample collection process.

DexCom has launched a registry to track the outcomes of patients using continuous glucose monitoring (CGM) in hospitals in response to the Covid-19 pandemic. Given the requirement to preserve personal protective equipment, minimise potential hospital staff exposure to Covid-19 and reduce the overall burden on nursing care, the Dexcom G6 CGM system has been made available to remotely monitor the glucose levels of all hospitalised patients during the Covid-19 pandemic.

Vivera Pharmaceuticals has launched BIOZONE, a device for sanitisation in high occupancy settings. This device features facial recognition, integrated biometrics, and a hospital grade organic sanitisation mist. It can detect body temperature, assign custom profiles for users, and offer surface disinfection of clothing and personal belongings. Vivera Pharmaceuticals chief medical officer Dr. Stephen McColgan said: “Public health requires a stepwise approach to comprehensive Covid-19 containment.”